NDC-11 (Package) | NDC-9 (Product) | Generic Name | Brand Name (Ascending) | Strength | SEER*Rx Category | Major Class | Minor Class | Administration Route | Package Effective Date | Package Discontinuation Date | Status |
---|---|---|---|---|---|---|---|---|---|---|---|
45802-0368-62 | 45802-0368 | Imiquimod | Imiquimod | 12.5 mg/.25g | Immunotherapy | Immunomodulator | Dermatological Agent | Topical | Nov. 9, 2010 | In Use | |
55513-0078-01 | 55513-0078 | Talimogene Laherparepvec | Imlygic | 1000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov. 2, 2015 | In Use | |
55513-0079-01 | 55513-0079 | Talimogene Laherparepvec | Imlygic | 100000000.0 [PFU]/mL | Immunotherapy | Therapeutic Cancer Vaccine | Oncolytic Virus | Intralesional | Nov. 2, 2015 | In Use | |
00069-0145-01 | 00069-0145 | Axitinib | Inlyta | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 27, 2012 | In Use | |
00069-0151-11 | 00069-0151 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 27, 2012 | In Use | |
63539-0044-01 | 63539-0044 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 27, 2012 | In Use | |
63539-0044-02 | 63539-0044 | Axitinib | Inlyta | 5.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 27, 2012 | In Use | |
63539-0026-01 | 63539-0026 | Axitinib | Inlyta | 1.0 mg/1 | Chemotherapy | Tyrosine Kinase Inhibitor | VEGFR | Oral | Jan. 27, 2012 | In Use | |
59572-0720-12 | 59572-0720 | Fedratinib Hydrochloride | Inrebic | 100.0 mg/1 | Chemotherapy | Enzyme Inhibitor | JAK2, FLT3 | Oral | Aug. 16, 2019 | In Use | |
00085-1235-01 | 00085-1235 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Oct. 3, 2010 | No Longer Used | ||
00085-1242-01 | 00085-1242 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Dec. 4, 2010 | No Longer Used | ||
00085-1254-01 | 00085-1254 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | Dec. 12, 2010 | No Longer Used | ||
00085-0539-01 | 00085-0539 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-0571-02 | 00085-0571 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-1110-01 | 00085-1110 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | June 4, 1986 | July 31, 2016 | No Longer Used | ||
00085-1133-01 | 00085-1133 | Interferon alfa-2b | Intron A | 19.2 ug/.5mL | Immunotherapy | Cytokine | Interferon | Intralesional, Intramuscular, Subcutaneous | June 4, 1986 | In Use | |
00085-1168-01 | 00085-1168 | Interferon alfa-2b | Intron A | 11.6 ug/.5mL | Immunotherapy | Cytokine | Interferon | Intramuscular, Subcutaneous | June 4, 1986 | In Use | |
00085-4350-01 | 00085-4350 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4351-01 | 00085-4351 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
00085-4352-01 | 00085-4352 | Interferon alfa-2b | Intron A | Immunotherapy | Cytokine | Interferon | Aug. 11, 2014 | In Use | |||
72485-0213-15 | 72485-0213 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Sept. 4, 2020 | In Use | |
00143-9583-01 | 00143-9583 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00143-9701-01 | 00143-9701 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00143-9702-01 | 00143-9702 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Dec. 20, 2010 | In Use | |
00703-4432-11 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 28, 2008 | Nov. 30, 2019 | No Longer Used |
00703-4432-81 | 00703-4432 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2015 | July 31, 2019 | No Longer Used |
00703-4434-11 | 00703-4434 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 100.0 mg/5mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 28, 2008 | March 31, 2019 | No Longer Used |
00703-4434-81 | 00703-4434 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 100.0 mg/5mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | July 1, 2015 | June 30, 2019 | No Longer Used |
25021-0214-02 | 25021-0214 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 20, 2012 | Dec. 27, 2016 | No Longer Used |
25021-0214-05 | 25021-0214 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 20, 2012 | Dec. 27, 2016 | No Longer Used |
25021-0230-02 | 25021-0230 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 15, 2014 | In Use | |
25021-0230-05 | 25021-0230 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Aug. 15, 2014 | In Use | |
47335-0937-40 | 47335-0937 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 21, 2008 | Jan. 24, 2017 | No Longer Used |
47335-0953-40 | 47335-0953 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 100.0 mg/5mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 21, 2008 | Jan. 24, 2017 | No Longer Used |
50742-0401-02 | 50742-0401 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 40.0 mg/2mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 5, 2017 | In Use | |
50742-0402-05 | 50742-0402 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 100.0 mg/5mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 5, 2017 | In Use | |
61703-0349-09 | 61703-0349 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 27, 2008 | In Use | |
61703-0349-16 | 61703-0349 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 27, 2008 | In Use | |
61703-0349-36 | 61703-0349 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Feb. 27, 2008 | In Use | |
63323-0193-02 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2009 | In Use | |
63323-0193-05 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2009 | In Use | |
63323-0193-52 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2009 | In Use | |
63323-0193-55 | 63323-0193 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2009 | In Use | |
72485-0211-02 | 72485-0211 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2019 | In Use | |
72485-0212-05 | 72485-0212 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | April 1, 2019 | In Use | |
16714-0725-01 | 16714-0725 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 15, 2017 | April 30, 2020 | In Use |
16714-0726-01 | 16714-0726 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 15, 2017 | April 30, 2020 | In Use |
23155-0179-31 | 23155-0179 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 20, 2012 | In Use | |
23155-0179-32 | 23155-0179 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | June 20, 2012 | June 21, 2012 | In Use |
66758-0048-01 | 66758-0048 | Irinotecan Hydrochloride | Irinotecan Hydrochloride | 20.0 mg/mL | Chemotherapy | Topoisomerase I Inhibitor | Camptothecin Analogs | Intravenous | Nov. 30, 2009 | May 27, 2018 | In Use |
Found 10,000 results in 9 milliseconds — Export these results